4Front Ventures Corp.

4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates in two segments, THC Cannabis and Cannabidiol (CBD) Wellness. It produces, cultivates, sells, and distributes cannabis and CBD. As of December 31, 2021, it operated six dispensaries in Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. In addition, the company sells equipment, supplies, and intellectual property to cannabis producers; imports and sale equipment and supplies; leases real estate properties to cannabis producers; offers consulting services; and operates cannabis dispensaries. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.

4Front Ventures Corp. trades as FFNTF on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $97.44M of revenue and -$91.65M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

4Front Ventures Corp. can be compared against peers such as Plant-Based Investment Corp., Quantum Medical Transport, Inc., Grapefruit USA, Inc., GelStat Corporation, Thoughtful Brands Inc., Pazoo, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $12,460, beta of 0.19, and return on equity of +177.9%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

FFNTF currently shows total debt of $209.84M and beta of 0.19. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: SC 13G/A (2025-08-05 00:00:00), 8-K (2025-06-26 00:00:00), 8-K (2025-06-10 00:00:00), 8-K (2025-05-27 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://4frontventures.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.